No Data
No Data
Gain Therapeutics Advances Parkinson's Therapy With Successful Phase 1 Results for GT-02287
The MAD part of the Phase 1 study was initiated in February, and all four MAD cohorts have completed daily oral dosing for 14 days.
Express News | Gain Therapeutics Inc - No Discontinuations or Serious Adverse Events Reported
Express News | Gain Therapeutics Inc - GT-02287 Trial in Parkinson's Disease Patients in Q4 2024
Express News | Gain Therapeutics Inc - Topline Data to Be Presented Mid-August
Express News | Gain Therapeutics Inc - GT-02287 Well Tolerated With No Serious Adverse Events
Express News | Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (Mad) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
Taco moo-ncher : what happened to your "hehehehe" uh?
TrytosaveabitOP Taco moo-ncher: Well I guess I just didn’t find anything humorous to laugh at with this post! Hehehe
Taco moo-ncher TrytosaveabitOP: ok![undefined undefined](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)